Search Bar & Filters
Found 36 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating a blended e-health intervention designed to improve fear of progression FOP in women with advanced or certain types of gynecologic or breast cancer. Fear of progression refers to the worry patients experience about their cancer growing or worsening, which is linked to distress, depression, and higher health care costs. This trial aims to determine whether the intervention is feasible, acceptable, and effective in reducing FOP and related psychological symptoms. Participants are randomly assigned to one of two groups over six weeks. One group takes part in the Mindful Living Program, which includes weekly group sessions and online sessions focusing on mindfulness and coping skills, daily practice of mindfulness techniques, check-in phone calls, and access to supportive online resources. The other group participates in the Navigating Cancer Program with similar group and online sessions and a check-in call but without the additional mindfulness practices or web resources. After the intervention, participants are followed up at 12 weeks. During the study, participants complete surveys measuring fear of progression, distress, anxiety, metacognitions, and mindfulness at the start, at six weeks, and again at 12 weeks. Researchers also monitor attendance, engagement, usability of the intervention, and recruitment and retention rates. The study includes remote group sessions, check-in calls, and access to online videos, a journal, and a community forum. Participation lasts approximately 12 weeks from baseline to follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new approach to prevent cardiovascular events in people at increased risk due to age and conditions like diabetes, prediabetes, or metabolic syndrome but who do not have symptoms of cardiovascular disease. The study compares a personalized care strategy based on the Cleerly Coronary Artery Disease CAD Staging System with the usual risk factor-based care. This approach aims to better identify and treat individuals with underlying atherosclerosis to reduce cardiovascular events. Participants are randomly assigned to one of two groups. The risk factor-based care group is managed by their usual healthcare providers, with oversight from a centralized cardiology team that monitors treatments and lab results without seeing coronary imaging results. The Cleerly stage-based care group receives personalized management from a remote cardiologist-led team using the Cleerly CAD Staging System, which includes coronary artery imaging, algorithm-driven medication adjustments, and education. Care is intensified if plaque worsens at 24 months. During the study, participants undergo assessments including coronary computed tomography angiography CCTA and lab tests. Researchers monitor cardiovascular events over an average of 3.5 years to compare the two care strategies. Medication use, lab values, and clinical outcomes related to cardiovascular and kidney health are tracked. The study includes electronic communication tools to support personalized care and aims to improve prevention through more precise disease staging and management.
Actively Recruiting
Researchers are evaluating disitamab vedotin alone or combined with pembrolizumab to treat urothelial cancer that expresses HER2. This study focuses on participants with locally advanced or metastatic urothelial cancer that cannot be removed by surgery. It aims to assess how well the drug works and to monitor the side effects experienced by participants. Participants receive disitamab vedotin intravenously every 2 weeks, either alone or with pembrolizumab given by intravenous infusion on Day 1 of each 6-week cycle. The study includes multiple cohorts receiving different combinations or monotherapy treatments. The treatment period and monitoring last approximately 2 years, with ongoing assessments of drug effects and safety. During the study, participants undergo regular evaluations including imaging scans to measure tumor response, laboratory tests, electrocardiograms to monitor heart function, and assessments of side effects. Researchers measure treatment response using established cancer evaluation criteria and track survival and disease control over about 3 years. Participants are closely monitored for adverse effects and blood levels of the drugs to understand how the treatments behave in the body.
Actively Recruiting
Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.
Actively Recruiting
Researchers are evaluating LY4005130, an intravenous drug, to see how well it is tolerated and what side effects may occur in adults with non-segmental vitiligo NSV. This randomized, double-blind, placebo-controlled study compares LY4005130 to a placebo over about 48 weeks, including screening. Participants must have NSV diagnosed for at least 3 months with specific body surface area involvement. Participants receive either LY4005130 or placebo intravenously during the treatment period. The study includes a 24-week treatment phase where the drug or placebo is administered, and blood tests are done to understand how the body processes the drug and how it affects the skin condition. The study drug is given through the vein in the arm. During the study, participants will have assessments including blood tests, skin evaluations using Vitiligo Area Scoring Indexes F-VASI and T-VASI, and skin biopsies to measure gene expression changes. Researchers will monitor safety, drug levels in the blood, and treatment effects up to 48 weeks. The main outcome is the percentage of participants achieving significant improvement in facial vitiligo area at week 24.
Actively Recruiting
Researchers are evaluating the effects of LY4005130 in adults with severe alopecia areata, a condition causing significant hair loss. This Phase 2 study aims to compare LY4005130s impact with a placebo, focusing on how well the drug works, how well it is tolerated, and what side effects may occur. Blood tests will also be conducted to understand how the drug is processed by the body and its biological effects. Participants will receive LY4005130 or placebo intravenously IV into a vein in the arm. The study uses a randomized, double-blind, placebo-controlled design to compare the study drug with placebo. The entire study duration is about 48 weeks, including a screening period. The main treatment phase assesses responses over 24 weeks, with additional follow-up for safety and drug effects. During the study, participants will undergo regular assessments including the Severity of Alopecia Tool SALT to measure hair loss improvement. Blood samples will be collected to analyze drug levels and gene expression changes in scalp biopsies. The study will monitor side effects and overall safety, helping researchers understand the treatments effects over nearly a year of participation.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of a new drug called GSK3862995B in adults with bronchiectasis, a chronic lung disease. This Phase 2 study also examines how the body processes the drug and checks for any immune reactions. Participants will be randomly assigned to receive one of two doses of GSK3862995B or a placebo to compare their effects on bronchiectasis. Participants will receive either Dose Level 1 or Dose Level 2 of GSK3862995B, or a matching placebo. The study uses a double-blind, randomized design, meaning neither participants nor researchers know who gets which treatment. The treatment period lasts up to 48 weeks, during which participants receive repeated doses. The study also includes assessments up to 72 weeks to monitor safety and immune responses. During the trial, participants will undergo evaluations including lung function tests, quality-of-life questionnaires, and monitoring of respiratory symptoms. Researchers will track the number of lung exacerbations, serious adverse events, laboratory tests, vital signs, and electrocardiograms to assess safety and effectiveness. Participants will be involved in regular visits and assessments throughout the treatment and follow-up periods, lasting up to about 72 weeks in total.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of the drug IMVT-1402 in adults with Graves disease who remain hyperthyroid despite treatment with antithyroid drugs. This randomized, double-blind, placebo-controlled Phase 2b trial aims to compare IMVT-1402 with a placebo by measuring thyroid hormone levels and antithyroid drug doses at 26 weeks. Participants receive IMVT-1402 through weekly injections under the skin at a dose of 600 mg. Different groups receive the drug for either 52 weeks continuously, 26 weeks followed by placebo for 26 weeks, or placebo only for 52 weeks. The study involves a parallel design where participants are assigned to one of these groups randomly. During the study, participants will have their thyroid hormone levels, including T3, FT3, FT4, and TSH, monitored regularly along with their antithyroid drug use. Assessments occur at various time points up to 104 weeks to evaluate thyroid function and antibody levels. Safety and tolerability will also be observed throughout the trial to understand the drugs effects over time.
Actively Recruiting
The trial investigates the long-term safety of avacopan in adults diagnosed with antineutrophil cytoplasmic antibody ANCA-associated vasculitis, a condition requiring immunosuppressive treatment. This phase 4, randomized, double-blind, placebo-controlled study aims to assess treatment-emergent adverse events and other safety markers over a period of up to 5 years. Participants include those newly diagnosed or experiencing a relapse of granulomatosis with polyangiitis or microscopic polyangiitis, with specific antibody and disease activity criteria. Participants are randomly assigned to one of three groups avacopan 30 mg twice daily for 5 years with standard immunosuppressive therapy, avacopan 30 mg twice daily for 1 year followed by placebo for 4 years with standard therapy, or placebo twice daily for 5 years with standard therapy. All participants receive background immunosuppressive care as determined by their doctors. Treatments are administered orally, and the study maintains double-blinding to compare safety and efficacy outcomes across groups. Throughout the study, participants undergo regular safety assessments including vital signs, blood tests, serum chemistry, and urine analysis to monitor any significant changes from baseline. Researchers evaluate adverse events, remission status, kidney function, health survey scores, and glucocorticoid or immunosuppressant use over the 5-year period. The study includes continuous monitoring for serious adverse events, treatment withdrawals, and deaths related to the intervention, ensuring detailed long-term safety data collection.
1-10 of 36
1